Maiwei Biopharma announced that it recently received a "Notice of Acceptance" from the National Medical Products Administration (NMPA) for its marketing authorization application (MAA) for 9MW0813 Injection, intended for the treatment of diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD). 9MW0813 Injection, a biosimilar to aflibercept (Aylea®), is a recombinant fusion protein formed by the extracellular binding domains of VEGFR-1 and VEGFR-2, combined with the Fc region of a human immunoglobulin. It binds to VEGF-A and PlGF.